De-risking the clinical development of cholesteryl ester transfer protein inhibitors: how much is good enough?

被引：6
|
作者：
Arsenault, Benoit J. [2 ]
Boekholdt, S. Matthijs [3 ]
Tardif, Jean-Claude [2 ]
Kastelein, John J. P. [1 ]
机构：
[1] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Montreal, Montreal Heart Inst, Quebec City, PQ, Canada
[3] Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands
来源：
EUROPEAN HEART JOURNAL | 2012年 / 33卷 / 13期
关键词：
OFF-TARGET TOXICITY; ENDOTHELIAL DYSFUNCTION; TORCETRAPIB; ALDOSTERONE; DISEASE; SAFETY;
D O I：
10.1093/eurheartj/ehr408
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1548 / 1550
页数：3
相关论文
共 50 条
  • [41] Immunotherapy development landscape for bone metastasis - need of predictive preclinical efficacy evaluation for de-risking clinical development
    Kahkonen, Tiina E.
    Halleen, Jussi M.
    MacRitchie, Gary
    Andersson, Ronnie M.
    Bernoulli, Jenni
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [42] Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib
    Miyares, Marta A.
    Davis, Kyle
    [J]. VASCULAR HEALTH AND RISK MANAGEMENT, 2012, 8 : 483 - 493
  • [43] Opportunities for use of neuroimaging in de-risking drug development and improving clinical outcomes in psychiatry: an industry perspective
    Etkin, Amit
    Powell, Jessica
    Savitz, Adam J.
    [J]. NEUROPSYCHOPHARMACOLOGY, 2024,
  • [44] 3D-QSAR Models on Cholesteryl Ester Transfer Protein Inhibitors
    Yan Lin-Fang
    Hu Gui-Xiang
    Xu Jing
    Zhao Wen-Na
    Yu Qing-Sen
    [J]. ACTA PHYSICO-CHIMICA SINICA, 2008, 24 (12) : 2249 - 2256
  • [45] Isolation of cholesteryl ester transfer protein inhibitors from Panax ginseng roots
    Kwon, BM
    Nam, JY
    Lee, SH
    Jeong, TS
    Kim, YK
    Bok, SH
    [J]. CHEMICAL & PHARMACEUTICAL BULLETIN, 1996, 44 (02) : 444 - 445
  • [46] Synthesis and evaluation of tetracyclic catechols as cholesteryl ester transfer protein (CETP) inhibitors
    Xia, Y
    Tsai, HG
    Chackalamannil, S
    Wang, YG
    Czarniecki, M
    Wang, S
    Clemmons, A
    Ahn, HS
    Boykow, GC
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1996, 212 : 175 - MEDI
  • [47] Anacetrapib: new hope for cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia
    Vergeer, Menno
    Kastelein, John J. P.
    [J]. NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2008, 5 (06): : 302 - 303
  • [48] New simple class of potent cholesteryl ester transfer protein inhibitors.
    Wang, LJJ
    Durley, RC
    Grapperhaus, ML
    Massa, MA
    Hickory, BS
    Mischke, DA
    Honda, DD
    Sikorski, JA
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 220 : U586 - U586
  • [49] Anacetrapib: new hope for cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia
    Menno Vergeer
    John JP Kastelein
    [J]. Nature Clinical Practice Cardiovascular Medicine, 2008, 5 : 302 - 303
  • [50] Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?
    Page, Michael M.
    Hooper, Amanda J.
    Burnett, John R.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (02) : 275 - 281
12345